AU2001232340A1 - Novel isoxazole and thiazole compounds and use thereof as drugs - Google Patents
Novel isoxazole and thiazole compounds and use thereof as drugsInfo
- Publication number
- AU2001232340A1 AU2001232340A1 AU2001232340A AU3234001A AU2001232340A1 AU 2001232340 A1 AU2001232340 A1 AU 2001232340A1 AU 2001232340 A AU2001232340 A AU 2001232340A AU 3234001 A AU3234001 A AU 3234001A AU 2001232340 A1 AU2001232340 A1 AU 2001232340A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- thiazole compounds
- atom
- drugs
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The present invention relates to novel isoxazole and thiazole compounds having an excellent lysophosphatidic acid (LPA) receptor antagonistic activity represented by general formula Ä1Ü or salts thereof: <IMAGE> wherein R1 and R2 represents an optionally substituted alkyl group or the like; R3 represents a hydrogen atom or the like; R4 represent a group selected from the group consisting of (I) optionally substituted phenyl, aryl, or heterocycle, (II) substituted or nonsubstituted alkyl, and (III) substituted or nonsubstituted alkenyl, alternatively, R3 and R4 may form a ring structure together with a carbon atom to which they bind; and X represents an oxygen atom or a sulfur atom, provided that, when R3 is a hydrogen atom, R4 represents a group other than methyl, and the use thereof as a medicine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-41922 | 2000-02-18 | ||
JP2000041922 | 2000-02-18 | ||
PCT/JP2001/001173 WO2001060819A1 (en) | 2000-02-18 | 2001-02-19 | Novel isoxazole and thiazole compounds and use thereof as drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001232340A1 true AU2001232340A1 (en) | 2001-08-27 |
Family
ID=18565067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001232340A Abandoned AU2001232340A1 (en) | 2000-02-18 | 2001-02-19 | Novel isoxazole and thiazole compounds and use thereof as drugs |
Country Status (11)
Country | Link |
---|---|
US (1) | US6964975B2 (en) |
EP (1) | EP1258484B1 (en) |
AT (1) | ATE420878T1 (en) |
AU (1) | AU2001232340A1 (en) |
CY (1) | CY1110263T1 (en) |
DE (1) | DE60137405D1 (en) |
DK (1) | DK1258484T3 (en) |
ES (1) | ES2320320T3 (en) |
PT (1) | PT1258484E (en) |
TW (1) | TWI288136B (en) |
WO (1) | WO2001060819A1 (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
EP1383778B1 (en) | 2001-01-30 | 2009-10-21 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
DE60234318D1 (en) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | FOR THE TREATMENT OF RESPIRATORY DISEASES, COMPRISING MEANS FOR THE CONTROL OF THE LPA RECEPTOR |
WO2003007991A1 (en) * | 2001-07-17 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Pancreatic juice secretion regulators comprising lpa receptor controller |
JP4596314B2 (en) * | 2002-05-28 | 2010-12-08 | 小野薬品工業株式会社 | β-alanine derivatives and uses thereof |
WO2004002530A1 (en) * | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | Remedy for chronic disease |
US7361368B2 (en) * | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
WO2004010949A2 (en) | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
WO2004031118A1 (en) | 2002-10-03 | 2004-04-15 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US8821473B2 (en) | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US7524638B1 (en) | 2003-06-27 | 2009-04-28 | Osi Pharmaceuticals, Inc. | Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease |
WO2005012269A1 (en) * | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | Novel azole compound |
US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
US8828433B2 (en) * | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
FR2889190A1 (en) | 2005-08-01 | 2007-02-02 | Merck Sante Soc Par Actions Si | New imidazole carboxamides, useful to treat e.g. pathologies associated with the insulin resistance syndrome, are fructose-1,6-biphosphatase inhibitors |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
EP1986623A2 (en) | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
EP1987013A1 (en) | 2006-02-09 | 2008-11-05 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US8741326B2 (en) | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
AU2007323557A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
NZ576893A (en) | 2006-11-21 | 2012-01-12 | Univ Virginia Patent Found | Tetralin analogs having sphingosine 1-phosphate agonist activity |
WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
DE102007047738A1 (en) * | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | imidazole derivatives |
JP5785491B2 (en) * | 2008-05-05 | 2015-09-30 | サノフイ | Acylamino substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
TWI450898B (en) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | Aryl isoxazole compounds with antitumoural activities |
WO2010068775A2 (en) * | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
US8722014B2 (en) * | 2009-05-01 | 2014-05-13 | Washington University | 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof |
GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
EP2481725B1 (en) | 2009-09-25 | 2015-03-04 | Astellas Pharma Inc. | Substituted amide compound |
GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
AR079022A1 (en) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | DERIVATIVES OF CYCLIC CARBOXYL ACID SUBSTITUTED WITH ACILAMINE, ITS USE AS PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD |
US20130253019A1 (en) * | 2010-06-15 | 2013-09-26 | John Howard Hutchinson | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
WO2011159635A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
JP5944823B2 (en) * | 2010-07-02 | 2016-07-05 | あすか製薬株式会社 | Heterocyclic compound and p27Kip1 degradation inhibitor |
ES2674174T3 (en) | 2010-12-07 | 2018-06-27 | Bristol-Myers Squibb Company | Polycyclic LPA1 antagonist and uses thereof |
US8785442B2 (en) * | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
EP2694496A1 (en) | 2011-04-05 | 2014-02-12 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
KR20140022048A (en) * | 2011-05-25 | 2014-02-21 | 인터뮨, 인크. | Pirfenidone and anti-fibrotic therapy in selected patients |
KR20140067048A (en) | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | Lysophosphatidic acid receptor antagonists |
WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
EP2783016A1 (en) | 2011-11-22 | 2014-10-01 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
EP2850062B1 (en) * | 2012-05-18 | 2017-07-19 | Sanofi | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
EP2940013B1 (en) | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
KR102090231B1 (en) * | 2013-03-15 | 2020-03-17 | 에피젠 바이오싸이언시즈, 아이엔씨. | Heterocyclic compounds useful in the treatment of disease |
EA038294B1 (en) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Heterocyclic compounds useful in the treatment of diseases |
CN104788343A (en) * | 2014-01-16 | 2015-07-22 | 同济大学 | Ortho-substituted allyl carbamate compound and preparation method thereof |
ES2824801T3 (en) * | 2014-06-27 | 2021-05-13 | Ube Industries | Halogen-substituted heterocyclic compound salt |
WO2016197009A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
PT3710438T (en) | 2017-12-19 | 2021-11-22 | Bristol Myers Squibb Co | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
ES2925626T3 (en) * | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Isoxazole-O-carbamoylcyclohexyl acids as LPA antagonists |
US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
US11261180B2 (en) | 2017-12-19 | 2022-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as LPA antagonists |
JP2021506878A (en) | 2017-12-19 | 2021-02-22 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Isoxazoleazine cyclohexyl as an LPA antagonist |
JP7467361B2 (en) * | 2018-06-18 | 2024-04-15 | エピゲン バイオサイエンシズ,インコーポレイテッド | Heterocyclic compounds useful in the treatment of diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1090795A (en) * | 1993-11-12 | 1995-05-29 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
US5861359A (en) * | 1995-07-25 | 1999-01-19 | Fmc Corporation | Herbicidal phenylmethoxphenyl heterocycles |
WO1998027213A1 (en) * | 1996-12-18 | 1998-06-25 | Medical Research Council | Lysophosphatidic acid acyltransferase gene and its use |
SE9904044D0 (en) * | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
GB0003256D0 (en) * | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
-
2001
- 2001-02-19 AU AU2001232340A patent/AU2001232340A1/en not_active Abandoned
- 2001-02-19 US US10/204,173 patent/US6964975B2/en not_active Expired - Fee Related
- 2001-02-19 ES ES01904545T patent/ES2320320T3/en not_active Expired - Lifetime
- 2001-02-19 WO PCT/JP2001/001173 patent/WO2001060819A1/en active Application Filing
- 2001-02-19 DE DE60137405T patent/DE60137405D1/en not_active Expired - Lifetime
- 2001-02-19 TW TW090103844A patent/TWI288136B/en not_active IP Right Cessation
- 2001-02-19 DK DK01904545T patent/DK1258484T3/en active
- 2001-02-19 PT PT01904545T patent/PT1258484E/en unknown
- 2001-02-19 EP EP01904545A patent/EP1258484B1/en not_active Expired - Lifetime
- 2001-02-19 AT AT01904545T patent/ATE420878T1/en active
-
2009
- 2009-03-31 CY CY20091100377T patent/CY1110263T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI288136B (en) | 2007-10-11 |
CY1110263T1 (en) | 2015-01-14 |
DE60137405D1 (en) | 2009-03-05 |
WO2001060819A1 (en) | 2001-08-23 |
DK1258484T3 (en) | 2009-04-20 |
EP1258484A4 (en) | 2003-04-23 |
PT1258484E (en) | 2009-04-03 |
ES2320320T3 (en) | 2009-05-21 |
US6964975B2 (en) | 2005-11-15 |
EP1258484A1 (en) | 2002-11-20 |
EP1258484B1 (en) | 2009-01-14 |
ATE420878T1 (en) | 2009-01-15 |
US20030114505A1 (en) | 2003-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001232340A1 (en) | Novel isoxazole and thiazole compounds and use thereof as drugs | |
IL147651A0 (en) | Isoxazoline derivative and herbicide containing the same as the active ingredient | |
FI943561A0 (en) | New compositions of matter | |
EP1310494A4 (en) | PPAR (delta) ACTIVATORS | |
GB0009532D0 (en) | Chemical compounds | |
PH12015501098A1 (en) | Antituberculous composition comprising oxazole compounds | |
ES2005186A6 (en) | Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds | |
EP1357124A4 (en) | Heterocyclic compounds and cerebral function improvers containing the same as the active ingredient | |
DE69119135D1 (en) | Substituted pyridine sulfonamide compounds, herbicidal compositions containing them and process for their preparation | |
BR9508676A (en) | Carbamolicarboxamide composition processes to prepare compounds and the composition and to control harmful fungi and use compost and compositions | |
ES2174077T3 (en) | ANTI-CHEMICAL HYDROXYLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS. | |
SE8101703L (en) | NEW ISOXAZOLD DERIVATIVES JUST SET FOR THEIR PREPARATION |